ライフサイエンスコーパス: stimulating factor

1 (Th1, Th2, and granulocyte-macrophage colony-stimulating factor).

2 except CTLA-4/granulocyte macrophage colony-stimulating factor.

3 tor alpha, and granulocyte-macrophage colony-stimulating factor.

4 sibly also for granulocyte-macrophage colony-stimulating factor.

5 phenotype with granulocyte-macrophage colony-stimulating factor.

6 t of IL-10 and granulocyte-macrophage colony-stimulating factor.

7 ctor-alpha and granulocyte macrophage colony-stimulating factor.

8 ponsiveness to granulocyte-macrophage colony-stimulating factor.

9 is factor inhibitors, and granulocyte colony-stimulating factors.

10 nd augments systemic levels of hematopoiesis-stimulating factors.

11 d osteoclasts are a source of bone formation-stimulating factors.

12 Colony-stimulating factor 1 (CSF-1) and interleukin (IL)-34 are

13 h gamma interferon (IFN-gamma) DNA or colony-stimulating factor 1 (CSF-1) DNA prior to ocular infecti

14 Colony-stimulating factor 1 (CSF-1), the cytokine acting as the

15 hat alloantibody can, in concert with colony-stimulating factor 1 (CSF-1)-dependent donor macrophages

16 resses OC differentiation by limiting colony-stimulating factor 1 (CSF-1)-dependent proliferation and

17 ) signaling and its ligands IL-34 and colony stimulating factor 1 (CSF-1).

18 alizing antibodies against macrophage colony-stimulating factor 1 (CSF1 or MCSF) or F4/80.

19 injury induced de novo expression of colony-stimulating factor 1 (CSF1) in injured sensory neurons.

20 we found sensitivity to inhibition of colony-stimulating factor 1 (CSF1) receptor (CSF1R), a receptor

21 Viral-mediated knockdown of neuronal colony stimulating factor 1 (CSF1) was used to modulate microgl

22 ly aggressive neoplasm, overexpresses colony-stimulating factor 1 (CSF1).

23 ption factor Wilms' Tumor 1 (WT1) and colony stimulating factor 1 (CSF1).

24 ly undescribed SG protein we term neutrophil stimulating factor 1 (NeSt1) activates primary mouse neu

25 We named this molecule neutrophil-stimulating factor 1 (NeSt1).

26 crophages (Mac(AIR)) that depend upon colony-stimulating factor 1 and are sustained by local prolifer

27 In response to liver injury, colony-stimulating factor 1 drives early monocyte-mediated myof

28 ral microglial reaction by removal of colony stimulating factor 1 from motoneurons or in CCR2 global

29 ed in the female mice and deletion of colony-stimulating factor 1 from sensory neurons, which prevent

30 ne, and depletion of microglia with a colony-stimulating factor 1 inhibitor, indicated that microglia

31 -to-tumour heterogeneity, response to colony-stimulating factor 1 receptor (CSF-1R) blockade and nano

32 nervous system (CNS) is dependent on colony stimulating factor 1 receptor (CSF-1R) signaling and its

33 SF) secreted by cancer cells binds to colony stimulating factor 1 receptor (CSF1-R) on macrophages an

34 Macrophage-targeted inhibition of the colony stimulating factor 1 receptor (CSF1R) by immunotherapy w

35 letal development through analysis of colony-stimulating factor 1 receptor (csf1r) function in the ze

36 Colony-stimulating factor 1 receptor (CSF1R) inhibition has bee

37 lowing removal via treatment with the colony stimulating factor 1 receptor (CSF1R) inhibitor PLX5622.

38 ronically activated microglia using a colony stimulating factor 1 receptor (CSF1R) inhibitor, Plexxik

39 ice were treated with pexidartinib, a colony-stimulating factor 1 receptor (CSF1R) inhibitor, to redu

40 Colony stimulating factor 1 receptor (CSF1R) plays key roles in

41 Microglia are dependent on colony-stimulating factor 1 receptor (CSF1R) signaling for thei

42 mune cells in brain, are dependent on colony stimulating factor 1 receptor (CSF1R) signaling for thei

43 observed that sustained inhibition of colony stimulating factor 1 receptor (CSF1R) using a CSF1R inhi

44 phages, including microglia, requires Colony Stimulating Factor 1 Receptor (CSF1R), a gene previously

45 Most macrophages require colony-stimulating factor 1 receptor (CSF1R), but some macropha

46 d that is specific for the macrophage colony-stimulating factor 1 receptor (CSF1R), the expression of

47 tumors and are normally dependent on colony-stimulating factor 1 receptor (CSF1R), we treated mice w

48 get TAM, and an antibody-neutralizing colony stimulating factor 1 receptor (CSF1R).

49 encephalopathy caused by mutations in colony stimulating factor 1 receptor (CSF1R).

50 to RSD, microglia were eliminated by colony-stimulating factor 1 receptor antagonism (PLX5622) and a

51 Elimination of microglia using the colony stimulating factor 1 receptor antagonist PLX5622 from th

52 In contrast, colony-stimulating factor 1 receptor blockade diminished C-C ch

53 ccumulation, and early death, through colony-stimulating factor 1 receptor inhibition (CSF1Ri) with p

54 e model of alcohol dependence using a colony stimulating factor 1 receptor inhibitor (PLX5622) to dep

55 at treatment with the pharmacological colony stimulating factor 1 receptor inhibitor PLX5622 specific

56 mice depleted of microglia by using a colony-stimulating factor 1 receptor inhibitor.

57 Treating MIA offspring by colony stimulating factor 1 receptor inhibitors induces depleti

58 thood, and reveals a potent effect of colony stimulating factor 1 receptor inhibitors on the correcti

59 lia (99%) by administering the CSF1R (colony-stimulating factor 1 receptor) antagonist PLX5622 before

60 croglia using PLX3397, which inhibits colony stimulating factor 1 receptor, ameliorated this delayed

61 of studies inhibiting the macrophage colony-stimulating factor 1 receptor,whereas the CD11b(+)/Ly6C(

62 omal dominant mutations in the CSF1R (colony-stimulating factor 1) gene.

63 interleukin 1 receptor antagonist and colony-stimulating factor 1, colony-stimulating factor 2 and in

64 is, illustrating the critical role of colony-stimulating factor 1-dependent monocyte/macrophage diffe

65 The cytokine colony stimulating factor-1 (CSF-1) acts as an important regula

66 Colony stimulating factor-1 (CSF-1) promotes placentation and c

67 ytes and, together with low levels of colony-stimulating factor-1 (CSF-1), inhibit their differentiat

68 crophage attractant and growth factor colony-stimulating factor-1 (CSF-1).

69 NA in breast cancer cells by limiting colony-stimulating factor-1 (CSF1)-dependent recruitment and M2

70 ting tumour-associated macrophages by colony-stimulating factor-1 receptor (CSF-1R) blockade in the K

71 Microglial depletion with the colony stimulating factor-1 receptor (CSF-1R) inhibitor PLX5622

72 and can be targeted via inhibition of colony-stimulating factor-1 receptor (CSF-1R) to regress high-g

73 is mediated by signaling through the colony-stimulating factor-1 receptor (CSF-1R) which is now know

74 e found that PLX3397, an inhibitor of colony stimulating factor-1 receptor (CSF-1R), blocks glioma pr

75 tion of mononuclear phagocytes is the colony stimulating factor-1 receptor (CSF-1R), which has two kn

76 ion is regulated by many factors, but colony stimulating factor-1 receptor (CSF1R) has emerged as a p

77 Interestingly, colony stimulating factor-1 receptor (CSF1R) is significantly i

78 eloid cells through the inhibition of colony-stimulating factor-1 receptor (CSF1Ri) to monitor the ch

79 Our results suggest that colony-stimulating factor-1 receptor inhibition may be a novel

80 his study evaluated the effect of the colony-stimulating factor-1 receptor inhibitor PLX5622 on exper

81 We then used the colony-stimulating factor-1 receptor inhibitor PLX5622 to deple

82 al giant cell tumors (TGCT), are rare colony stimulating factor-1(CSF-1)-driven proliferative disorde

83 responses via inducing chemokine and colony stimulating factor 2 (CSF2) expression in kidney residen

84 nist and colony-stimulating factor 1, colony-stimulating factor 2 and interleukin 17F, without effect

85 factor; genetic mutations in CSF2RA (colony-stimulating factor 2 receptor alpha-subunit), MARS (meth

86 We hypothesized that thrombin-induced colony-stimulating factor-2 (CSF-2) in decidual cells triggers

87 days 2-5 plus granulocyte macrophage colony-stimulating factor (250 mug/m(2) per dose) subcutaneousl

88 Here we identify that colony stimulating factor 3 (CSF3), released during acute infla

89 prevalence (>80%) of mutations in the colony-stimulating factor 3 receptor (CSF3R).

90 nterleukin 10 receptor alpha subunit, colony stimulating factor 3 receptor and toll-like receptor 7 m

91 eukin-6, tumour necrosis factor-a and colony-stimulating factor 3), and antiinflammatory markers (inc

92 Colony-stimulating factor-3 receptor (CSF3R)-T618I is a recurre

93 y cycles); or intravenous granulocyte colony-stimulating factor (300 mug/m(2) per day or 5 mug/kg per

94 (2)/dose on days 1-5; and granulocyte-colony stimulating factor 5 ug/kg/dose, days 1-5 and day 15 thr

95 kin-3, interleukin-6, and granulocyte colony-stimulating factor (5 GFs) either alone or combined.

96 ly due to its induction by macrophage colony-stimulating factor and downregulation by IFN-gamma.

97 hages easily in vitro with macrophage colony-stimulating factor and human serum.

98 creased responsiveness to granulocyte colony-stimulating factor and increased leukemogenesis).

99 cytokines (eg, granulocyte-macrophage colony-stimulating factor and interferon-gamma) critical to the

100 d responses to granulocyte-macrophage colony-stimulating factor and markedly decreased activity of al

101 oglial chemokines, such as macrophage-colony-stimulating factor and monokine induced by interferon-ga

102 s in adulthood and raised granulocyte-colony stimulating factor and neutrophil counts/activity postsu

103 expression of granulocyte-macrophage colony-stimulating factor and the C-X-C chemokine receptor type

104 and CD1a with granulocyte-macrophage colony-stimulating factor and transforming growth factor beta a

105 crosis factor, granulocyte-macrophage colony-stimulating factor) and cytolytic degranulation pathway

106 ion of cytokines including macrophage colony-stimulating factor, and 3-fold increased osteoclast numb

107 lating factor, granulocyte-macrophage colony-stimulating factor, and C-reactive protein at enrollment

108 id IL-1alpha, IL-6, IL-8, granulocyte colony-stimulating factor, and GM-CSF levels.

109 e, IL-8, IL-1alpha, IL-6, granulocyte colony-stimulating factor, and GM-CSF levels.

110 factor alpha, granulocyte-macrophage colony-stimulating factor, and granzyme B), and they were able

111 ne, high-dose cytarabine, granulocyte colony-stimulating factor, and mitoxantrone), or reduced-dose C

112 cell adhesion molecule-1, granulocyte colony-stimulating factor, and soluble Fas.

113 eron-gamma and granulocyte-macrophage colony-stimulating factor are requisite factors in the tumor th

114 PROSTVAC plus granulocyte-macrophage colony-stimulating factor (Arm VG; n = 432), or placebo (Arm P;

115 cellulose) and granulocyte-macrophage colony-stimulating factor as adjuvants displayed favourable saf

116 reports have identified hematopoietic colony-stimulating factors as important regulators of tumor- an

117 nscriptional repressor of autocrine motility-stimulating factor Autotaxin (ATX).

118 ented by interleukin-1 or granulocyte colony-stimulating factor blockade, revealing remarkable plasti

119 depletion and granulocyte-macrophage colony-stimulating factor blockade.

120 Neutralizing granulocyte-colony stimulating factor blocked susceptibility to disease in

121 expression of granulocyte-macrophage colony-stimulating factor by renal tubular cells, which directl

122 -kappaB) ligand (RANKL), a potent osteoclast-stimulating factor, by human periodontal ligament (hPDL)

123 imulation with granulocyte-macrophage colony-stimulating factor, compared with cells transfected with

124 enced human monocyte responses to the colony-stimulating factors CSF-1 and CSF-2 in vitro.

125 Colony-stimulating factor (CSF)-1 and interleukin (IL)-34 are m

126 l remodeling of neurons via increased colony-stimulating factor (CSF)-1 in the medial PFC.

127 mmunity-related markers calprotectin, colony-stimulating factor (CSF)-1, macrophage migration inhibit

128 xpression and secretion of macrophage colony-stimulating factor CSF1 by tumor cells.

129 nals from the receptor for macrophage colony-stimulating factor, CSF1R.

130 d bacterial replication in macrophage colony-stimulating factor-differentiated macrophages more than

131 s more than in granulocyte-macrophage colony-stimulating factor-differentiated macrophages.

132 poietic stress, including granulocyte colony-stimulating factor, do not increase the mutation burden

133 hemotactic protein-3, and granulocyte-colony stimulating factor during the acute phase (p < 0.05).

134 in tumor-bearing mice the macrophage colony-stimulating factor elevates the myeloid cell levels of n

135 n NK cell-deficient mice, granulocyte colony-stimulating factor-expanded neutrophils show an inhibito

136 , meropenem, and adjuvant granulocyte colony-stimulating factor for confirmed melioidosis sepsis in 1

137 proinflammatory cytokine granulocyte-colony-stimulating factor (G-CSF or Csf-3) as a key mediator of

138 on mutations; therapeutic granulocyte colony-stimulating factor (G-CSF) administration early in life

139 hen forced into cycle via granulocyte colony-stimulating factor (G-CSF) administration.

140 f the therapeutic protein granulocyte colony-stimulating factor (G-CSF) against storage at 4 degrees

141 the neuroactive cytokine granulocyte-colony stimulating factor (G-CSF) alters cocaine reward and rei

142 oliferation was driven by granulocyte colony-stimulating factor (G-CSF) and administration of neutral

143 migration by antagonizing granulocyte colony-stimulating factor (G-CSF) and chemokine receptor-mediat

144 he safety and efficacy of granulocyte colony-stimulating factor (G-CSF) and haemopoietic stem-cell in

145 verely reduced amounts of granulocyte colony-stimulating factor (G-CSF) and of nitric oxide (NO) upon

146 effects of the cytokines, granulocyte-colony stimulating factor (G-CSF) and stem cell factor (SCF) in

147 our group has identified granulocyte-colony stimulating factor (G-CSF) as a neuroactive cytokine tha

148 with a five-day course of granulocyte colony stimulating factor (G-CSF) as the most common regimen us

149 current administration of granulocyte colony-stimulating factor (G-CSF) enhanced RT-mediated antitumo

150 he efficacy and safety of granulocyte colony-stimulating factor (G-CSF) in steroid nonresponders.

151 Granulocyte colony-stimulating factor (G-CSF) is used clinically to treat l

152 ve protein 1 (MCP-1), and granulocyte colony-stimulating factor (G-CSF) levels in the amniotic fluid

153 ulin (ATG) plus pegylated granulocyte colony-stimulating factor (G-CSF) preserves beta-cell function

154 o describe outcomes after granulocyte colony-stimulating factor (G-CSF) prophylaxis in patients with

155 t, 2 designs bound to the granulocyte colony-stimulating factor (G-CSF) receptor and exhibited potent

156 Using a granulocyte-colony stimulating factor (G-CSF) receptor knockout mouse model

157 f the Csf3r gene, reduced granulocyte colony-stimulating factor (G-CSF) receptor levels, attenuation

158 d HSPC mobilization after granulocyte colony-stimulating factor (G-CSF) stimulation.

159 rculation by the cytokine granulocyte colony-stimulating factor (G-CSF) through complex mechanisms.

160 on in neuronal cells, and granulocyte colony-stimulating factor (G-CSF) was chosen, due to its clinic

161 ollowing VSG, circulating granulocyte-colony stimulating factor (G-CSF) was increased in mice, and wa

162 2-microglobulin (beta2m), granulocyte colony stimulating factor (G-CSF), and three monoclonal antibod

163 ting protein 78 (ENA-78), granulocyte colony stimulating factor (G-CSF), granulocyte macrophage colon

164 y factors including IL-8, granulocyte-colony stimulating factor (G-CSF), IL-33, IL-11, IL-1alpha, and

165 ficantly higher levels of granulocyte colony-stimulating factor (G-CSF), interleukin 1alpha (IL-1alph

166 MIP-1beta, granulocyte colony-stimulating factor (G-CSF), interleukin-12/23 (IL-12/23)

167 me are often treated with granulocyte colony-stimulating factor (G-CSF), which can increase neutrophi

168 ant (tx), tumor (tm), and granulocyte-colony stimulating factor (g-csf)-expanded MDSCs or depletion o

169 Nociceptor neurons drive granulocyte colony-stimulating factor (G-CSF)-induced HSC mobilization via

170 ars in the circulation of granulocyte colony-stimulating factor (G-CSF)-treated donors (GDs) consists

171 dard multi-day regimen of granulocyte colony-stimulating factor (G-CSF).

172 ue, in part via increased granulocyte-colony stimulating factor (G-CSF).

173 e to the up-regulation of granulocyte-colony stimulating factor (G-CSF); these effects are reversed f

174 (interleukine (IL)-1beta, granulocyte colony stimulating factor (G.CSF), IL-13, IL-6, IL-12, interfer

175 ifferent ligands based on granulocyte colony-stimulating factor GCSF homo-dimeric derivatives linked

176 gand (FL) (days 1-10) and granulocyte colony-stimulating factor (GCSF) (days 4-10).

177 Human granulocyte colony-stimulating factor (GCSF) is a well-known cytokine for n

178 th incomplete response to granulocyte colony-stimulating factor (GCSF) treatment decreased serum 1,5A

179 d to 1) ATG and pegylated granulocyte colony-stimulating factor (GCSF), 2) ATG alone, or 3) placebo.

180 IL-6, IL-8, IL-10, IL-15, granulocyte colony-stimulating factor (GCSF), MCP-1, tumor necrosis factor

181 We also show that granulocyte colony-stimulating factors (GCSF and GM-CSF) enhance swarming a

182 bodies against granulocyte-macrophage colony-stimulating factor; genetic mutations in CSF2RA (colony-

183 Granulocyte-macrophage colony-stimulating factor (GM-CSF or Csf-2) is a pro-inflammato

184 s decreases in granulocyte-macrophage colony-stimulating factor (GM-CSF) (6.6-fold), RANTES (14.8-fol

185 The cytokine granulocyte-macrophage colony-stimulating factor (GM-CSF) (encoded by Csf2) is a key c

186 in (IL)-12 and granulocyte-macrophage colony-stimulating factor (GM-CSF) (oAd) and DCs for sustained

187 y with 200 mug granulocyte-macrophage colony-stimulating factor (GM-CSF) adjuvant or 200 mug GM-CSF a

188 ators, such as granulocyte-macrophage colony-stimulating factor (GM-CSF) and C-C motif chemokine liga

189 thers, such as granulocyte-macrophage colony-stimulating factor (GM-CSF) and interleukin-3 (IL-3), ha

190 the cytokines granulocyte-macrophage colony-stimulating factor (GM-CSF) and interleukin-4 (IL-4).

191 breast cancer: granulocyte macrophage colony-stimulating factor (GM-CSF) and matrix metallopeptidase

192 cer cell-derived granulocyte-monocyte colony-stimulating factor (GM-CSF) and occurred in a Stat5-depe

193 d neutralizing granulocyte-macrophage colony-stimulating factor (GM-CSF) as a potential strategy to m

194 ma, IL-22, and granulocyte-macrophage colony-stimulating factor (GM-CSF) as well as transcription fac

195 IP-1alpha) and granulocyte-macrophage colony-stimulating factor (GM-CSF) can enhance the immunogenici

196 ls loaded with granulocyte-macrophage colony-stimulating factor (GM-CSF) for concentrating dendritic

197 Benefits of granulocyte-macrophage colony-stimulating factor (GM-CSF) for improving walking abilit

198 Recently, granulocyte-macrophage colony stimulating factor (GM-CSF) has been identified as a cyt

199 Granulocyte-macrophage colony-stimulating factor (GM-CSF) has many more functions than

200 nce shows that granulocyte macrophage colony-stimulating factor (GM-CSF) has progression-promoting po

201 involvement of granulocyte-macrophage colony stimulating factor (GM-CSF) in nociceptor activation in

202 he presence of granulocyte-macrophage colony-stimulating factor (GM-CSF) in vitro.

203 Granulocyte-macrophage colony-stimulating factor (GM-CSF) is a multipotent cytokine th

204 the increased granulocyte-macrophage colony-stimulating factor (GM-CSF) level in the EDM-TTF-1(+) co

205 Granulocyte-macrophage colony-stimulating factor (GM-CSF) produced by T helper 17 (Th1

206 ta that drives granulocyte-macrophage colony-stimulating factor (GM-CSF) production by CD4(+) T cells

207 s that secrete granulocyte-macrophage colony-stimulating factor (GM-CSF) promote graft-versus-host di

208 tor (M-CSF) or granulocyte macrophage colony-stimulating factor (GM-CSF) resembled in vivo inflammato

209 nisms by which granulocyte/macrophage-colony stimulating factor (GM-CSF) signaling normally maintains

210 y defenses via granulocyte-macrophage colony-stimulating factor (GM-CSF) signaling, which stimulates

211 disruption of granulocyte-macrophage colony-stimulating factor (GM-CSF) signalling and can be autoim

212 Granulocyte-macrophage colony-stimulating factor (GM-CSF) signalling in astrocytes dri

213 blasts produce granulocyte/macrophage colony-stimulating factor (GM-CSF) that acts locally and distal

214 Ipilimumab and granulocyte macrophage colony stimulating factor (GM-CSF) was presented in the supplem

215 Granulocyte-macrophage colony-stimulating factor (GM-CSF), a myelopoietic growth facto

216 ukin-3 (IL-3), granulocyte-macrophage colony-stimulating factor (GM-CSF), and stem cell factor (SCF)

217 actor (G-CSF), granulocyte macrophage colony stimulating factor (GM-CSF), IL-8, IL-18, monocyte chemo

218 a (TNF-alpha), granulocyte macrophage colony stimulating factor (GM-CSF), interleukin 6 (IL-6) among

219 Granulocyte-macrophage colony-stimulating factor (GM-CSF), mainly produced by MDSCs, w

220 IL-4), but not granulocyte-macrophage colony-stimulating factor (GM-CSF), signaling.

221 s the cytokine granulocyte-macrophage colony-stimulating factor (GM-CSF), the Toll-like-receptor-9 ag

222 enic levels of granulocyte-macrophage colony stimulating factor (GM-CSF), through deregulation of the

223 production of granulocyte macrophage-colony stimulating factor (GM-CSF), which recruits and maintain

224 ophins and the granulocyte-macrophage colony-stimulating factor (GM-CSF)-CC-chemokine ligand 17 (CCL1

225 ells inhibited granulocyte-macrophage colony-stimulating factor (GM-CSF)-induced CD103(+) DC differen

226 mat, CCR6, and granulocyte macrophage colony-stimulating factor (GM-CSF).

227 sensitivity to granulocyte-macrophage colony-stimulating factor (GM-CSF).

228 by exposure to granulocyte-macrophage colony-stimulating factor (GM-CSF).

229 ium to produce granulocyte-macrophage colony-stimulating factor (GM-CSF).

230 IL-3, IL-5 or granulocyte-macrophage colony-stimulating factor (GM-CSF).

231 that targeting granulocyte-macrophage colony-stimulating factor (GM-CSF; an agonist cytokine linked w

232 ukin-6 [IL-6], granulocyte-macrophage colony-stimulating factor [GM-CSF], CCL3, CCL5, and CXCL9) or T

233 , IL-13, IL-6, granulocyte-macrophage colony-stimulating factor [GM-CSF], IL-4, and MIP-1alpha) respo

234 , we show that granulocyte-macrophage colony-stimulating factor (GMCSF) is a key CRS-promoting protei

235 L-1beta, IL-1alpha, IL-6, granulocyte-colony stimulating factor, granulocyte-macrophage colony-stimul

236 intuximab, and granulocyte-macrophage colony-stimulating factor (I/T/DIN/GM-CSF) demonstrated activit

237 e secretion of granulocyte macrophage-colony stimulating factor, IL-12, -13, and -15, which was preve

238 adjunctive treatment with granulocyte colony-stimulating factor in 1998.

239 pathophysiologic role of granulocyte colony-stimulating factor in exacerbation of preexisting GN.

240 c responsibilities when triggered by various stimulating factors in the tumor microenvironment (acidi

241 tic cytokines (especially granulocyte colony-stimulating factor) in shortening the duration of neutro

242 tment with a high dose of granulocyte colony-stimulating factor increases neutrophil production and r

243 rleukin-4 plus granulocyte macrophage-colony stimulating factor)-induced activation of Rac1, in bone

244 clear factor kappaB ligand/macrophage colony-stimulating factor induction of nuclear factor of activa

245 kines, such as granulocyte macrophage colony-stimulating factor, interferon-gamma, interleukin-1alpha

246 cytokines (interleukin 6, granulocyte colony-stimulating factor, interleukin 1 receptor antagonist, a

247 lper 17 cells (granulocyte-macrophage colony-stimulating factor, interleukin [IL]17A, IL17F, IL22, an

248 Granulocyte-macrophage colony-stimulating factor is a potential therapeutic target to

249 aphy of recombinant human granulocyte colony stimulating factor is demonstrated.

250 acrophages stimulated with macrophage colony-stimulating factor (M-CSF) and granulocyte-M-CSF (GM-CSF

251 n-vitro in the presence of macrophage colony stimulating factor (M-CSF) and receptor activator of nuc

252 or kappa B ligand (RANKL), macrophage colony-stimulating factor (M-CSF) and transforming growth facto

253 come was the production of macrophage-colony stimulating factor (M-CSF) and tumor necrosis factor-alp

254 -kappaB ligand (RANKL) and macrophage colony-stimulating factor (M-CSF) as well as BMSC CM from each

255 nd hyper-responsiveness to macrophage colony-stimulating factor (M-CSF) in bone marrow macrophages.

256 onocytes differentiated by macrophage colony-stimulating factor (M-CSF) or granulocyte macrophage col

257 topoietic progenitors with macrophage colony-stimulating factor (M-CSF) resulted in mTORC1-dependent

258 Macrophage colony stimulating factor (M-CSF) was implicated as a contribut

259 hage glucose metabolism by macrophage colony-stimulating factor (M-CSF; inflammation resolving) and g

260 ma IL-10, GzB, granulocyte macrophage colony-stimulating factor, macrophage inflammatory protein 1 al

261 First, macrophage colony stimulating factor (MCSF) secreted by cancer cells binds

262 bine plus cytarabine plus granulocyte colony-stimulating factor, mitoxantrone plus cytarabine, or hig

263 unctional human MEPs from granulocyte colony-stimulating factor-mobilized peripheral blood and bone m

264 ismatched, unrelated, and granulocyte colony-stimulating factor-mobilized peripheral blood stem cell

265 glycoprotein, granulocyte-macrophage colony-stimulating factor, modeling both reducing and oxidizing

266 r (TNF) alpha, granulocyte-macrophage colony-stimulating factor, monocyte chemoattractant 1, macropha

267 l depletion or granulocyte-macrophage colony-stimulating factor neutralization inhibited DC and T-cel

268 neutrophil functions via granulocyte colony-stimulating factor neutralization significantly diminish

269 ctivity, whereas coronavirus nsp16 needs the stimulating factor nsp10 for its full activity.

270 Akt induced by granulocyte-macrophage colony-stimulating factor or interleukin-4.

271 plus prednisone daily and granulocyte colony-stimulating factor) or the other androgen-signaling-targ

272 (P < 0.01) and granulocyte-macrophage colony-stimulating factor (P < 0.001), thus contributing to mig

273 Gylated recombinant human granulocyte colony stimulating factor (pegfilgrastim) is used clinically to

274 Filgrastim, an analog for granulocyte colony-stimulating factor produced by recombinant DNA technolog

275 ted numbers of granulocyte-macrophage colony-stimulating factor-producing B cells within pericardial

276 ma, IL-15, and granulocyte-macrophage colony-stimulating factor protected from subsequent malaria, in

277 tivating mutations in the granulocyte colony stimulating factor receptor (CSF3R), cooperate with loss

278 ons in CSF3R encoding the granulocyte colony-stimulating factor receptor (G-CSFR) in approximately 80

279 nding protein, cadherin-5, macrophage colony-stimulating factor receptor (MCSFR), paraoxonase 1 (norm

280 or family (CSF3R/CSF3) and macrophage colony-stimulating factor receptor family (CSF1R/IL34/CSF1) res

281 primarily governed by the granulocyte colony-stimulating factor receptor family (CSF3R/CSF3) and macr

282 mice (mice expressing the macrophage colony-stimulating factor receptor GFP transgene throughout the

283 R], IL-5R, and granulocyte-macrophage colony stimulating factor receptor) signaling in the absence of

284 (erythropoietin receptor, granulocyte colony-stimulating factor receptor, and MPL) whereas CALR or MP

285 ytokine receptors, except granulocyte colony-stimulating factor receptor, which supported only transi

286 Granulocyte-macrophage colony-stimulating factor-receptor-alpha expression patterns we

287 Granulocyte-macrophage colony-stimulating factor-receptor-alpha was predominantly expr

288 surface IL-3 and granulocyte-monocyte colony-stimulating factor receptors, CD69, CD44, and CD23 and d

289 ombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF) as a model drug, the prese

290 Second, colony stimulating factors, secreted by cancer cells, polarize

291 tif) ligand 9, granulocyte-macrophage colony-stimulating factor, soluble tumor necrosis factor recept

292 ealing changes, including recruitment of CPA-stimulating factors, that explain U1-CPAFs' switch from

293 controlled by granulocyte-macrophage colony-stimulating factor, through the activation of the STAT5

294 ium levels and granulocyte macrophage-colony-stimulating factor, tumor necrosis factor alpha, and int

295 mg daily prednisone, and granulocyte colony-stimulating factor) versus abiraterone (1000 mg orally o

296 N-gamma, IL-12, IL-6, and granulocyte colony-stimulating factor were significantly reduced, while mon

297 Therapeutic colony-stimulating factors were associated with a 1.42-day redu

298 s encodes the receptor for macrophage colony-stimulating factor, which controls the proliferation, di

299 Also, cancer cells secrete stimulating factors, which polarize tumor-associated mac

300 sensitivity to granulocyte-macrophage colony-stimulating factor with myeloid cell dysplasia and ineff